- Home
- SVRA
SVRA
Savara Inc.
as 07-26-2024 4:00pm EST
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 814.0M | IPO Year: | N/A |
| Target Price: | $11.80 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.12 - $5.70 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Savara Inc. (SVRA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Pauls Matthew | SVRA | CHIEF EXECUTIVE OFFICER | Dec 28 '23 | Sell | $4.71 | 84,000 | $395,900.40 | 1,302,674 | SEC Form 4 |
| Lowrance David L | SVRA | CHIEF FINANCIAL OFFICER | Dec 28 '23 | Sell | $4.71 | 10,000 | $47,131.00 | 342,355 | SEC Form 4 |
Latest Savara Inc. News
SVRA Breaking Stock News: Dive into SVRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
22 days ago
Savara Inc.'s (NASDAQ:SVRA) high institutional ownership speaks for itself as stock continues to impress, up 14% over last week
Insider Monkey
a month ago
Did Savara Inc. (SVRA) Receive a Good Rating from Wall Street Analysts in Q1?
MT Newswires
a month ago
Savara Prices $100 Million Common Shares Offering
Business Wire
a month ago
Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
MT Newswires
a month ago
JMP Securities Adjusts Price Target on Savara to $10 From $8, Maintains Market Outperform Rating
MT Newswires
a month ago
Oppenheimer Adjusts Price Target on Savara to $15 From $11, Maintains Outperform Rating
MT Newswires
a month ago
Guggenheim Adjusts Price Target on Savara to $10 From $8, Maintains Buy Rating
MT Newswires
a month ago
HC Wainwright Raises Savara Price Target to $10 From $6, Maintains Buy Rating
Compare SVRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SVRA Savara Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.